Trial Profile
A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler compared with usual maintenance therapy in subjects with Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms SLS; SLS Asthma
- Sponsors GlaxoSmithKline; GSK
- 07 Feb 2022 Results of post-hoc analysis comparing the effects of switching from a pressurised metered dose inhaler (pMDI)-based to a dry powder inhaler (DPI)-based maintenance therapy versus continued usual care on greenhouse gas emissions and asthma control, published in the Thorax.
- 11 Jan 2020 Results published in the Advances in Therapy
- 14 Nov 2018 Results analysing the economic impact of results from Salford Lung Study in asthma when applied to Spain presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research